Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
Edwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 2, pp. 100523-100523
Open Access | Times Cited: 24

Showing 24 citing articles:

COVID‐19 and plasma cells: Is there long‐lived protection?*
Doan C. Nguyen, Pedro A. Lamothe, Matthew C. Woodruff, et al.
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 40-63
Open Access | Times Cited: 41
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
Alexander P. Underwood, Christina Sølund, Carlota Fernandez-Antunez, et al.
EBioMedicine (2023) Vol. 89, pp. 104475-104475
Open Access | Times Cited: 16
Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2
Jordana Muñoz‐Basagoiti, Fábio L. Monteiro, Lauren R. H. Krumpe, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 10
Open Access | Times Cited: 15
Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
Julià Blanco, Benjamin Trinité, Joan Puig‐Barberà
Influenza and Other Respiratory Viruses (2025) Vol. 19, Iss. 1
Open Access
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters
Edwards Pradenas, Víctor Urrea, Sílvia Marfil, et al.
Research Square (Research Square) (2025)
Closed Access
Sustained seropositivity up to 20.5 months after COVID-19
Carlota Dobaño, Anna Ramírez‐Morros, Selena Alonso, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
Lorna Leal, Judit Pich, Laura Ferrer, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 8
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
Erola Ainsua‐Enrich, Núria Pedreño-López, Carmen Bracke, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105455-105455
Open Access | Times Cited: 13
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
Edwards Pradenas, Sílvia Marfil, Víctor Urrea, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106457-106457
Open Access | Times Cited: 7
Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
Edwards Pradenas, María Ubals, Víctor Urrea, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities
Macedonia Trigueros, Edwards Pradenas, Dolors Palacín, et al.
Age and Ageing (2022) Vol. 51, Iss. 5
Open Access | Times Cited: 9
Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study
Ángel Estella, María Luisa Cantón‐Bulnes, Laura Muñoz, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 11, pp. 1086-1086
Open Access | Times Cited: 11
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
Eugenia Abellá, Macedonia Trigueros, Edwards Pradenas, et al.
Life Science Alliance (2022) Vol. 5, Iss. 12, pp. e202201479-e202201479
Open Access | Times Cited: 6
Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection
Sindhu Vangeti, Sivakumar Periasamy, Peifang Sun, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 6
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Responses After Community Infections in Children and Adults
Fatimah S. Dawood, Alexia Couture, Xueyan Zhang, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 3
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors
Eudald Felip, Edwards Pradenas, Margarita Romeo, et al.
Molecular Oncology (2022) Vol. 17, Iss. 4, pp. 686-694
Open Access | Times Cited: 5
Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study
Manjula Gunawardana, Simon G. Webster, Sofía Lucila Rodríguez Rivera, et al.
Communications Medicine (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 4
A Prospective Study of the Serological, Clinical, and Epidemiological Features of a SARS-CoV-2 Positive Pediatric Cohort
Ignacio Callejas Caballero, Alba Ruedas-López, Arantxa Berzosa, et al.
Children (2022) Vol. 9, Iss. 5, pp. 665-665
Open Access | Times Cited: 3
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Carlos Ávila‐Nieto, Júlia Vergara‐Alert, Pep Amengual-Rigo, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients
Ivette Orosa Vázquez, Marianniz Díaz-Hernández, Yaíma Zúñiga Rosales, et al.
Journal of Immunology Research (2024) Vol. 2024, Iss. 1
Open Access
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant
Carlos Ávila‐Nieto, Júlia Vergara‐Alert, Pep Amengual-Rigo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
Erola Ainsua‐Enrich, Núria Pedreño-López, Carmen Bracke, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 1
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 and golden Syrian hamster upon SARS-CoV-2 infection.
Jorge Carrillo, Carlos Ávila‐Nieto, Júlia Vergara‐Alert, et al.
Research Square (Research Square) (2023)
Open Access
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant
Carlos Ávila‐Nieto, Júlia Vergara‐Alert, Pep Amengual-Rigo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top